{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:01:29Z","timestamp":1792213289679,"version":"4.4.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Three percent hypertonic saline (3NS) is an established treatment for severe hyponatremia. The optimal regimen for administering 3NS for severe hyponatremia, with the aim to minimize side effects is not known. This systematic review and meta-analysis aimed to evaluate the safety profile of rapid intermittent bolus (RIB) versus slow continuous infusion (SCI) of 3NS for managing symptomatic severe hyponatremia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Databases were searched for studies evaluating the use of RIB versus SCI\/conventional therapy of 3NS for managing symptomatic severe hyponatremia. The primary outcome was to evaluate the occurrence of overcorrection of hyponatremia. Secondary outcomes were to evaluate the need for relowering therapy, duration of hospital stay, changes in sodium levels, osmotic demyelination syndrome (ODS), and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data from three studies (290 patients) with severe hyponatremia was analyzed. Patients receiving RIB had a similar occurrence of overcorrection (relative risk [RR]: 1.59 [0.40, 6.35]; I2 = 61%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.51), need for relowering treatment to bring down serum sodium back to the normal range (RR: 2.53 [0.32, 20.20]; I2 = 81%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.38), ODS (RR: 2.24 [0.09, 57.18];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.63) and mortality (RR: 0.51 [0.08, 3.30]; I2 = 31%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.48), as compared to those receiving SCI. Patients receiving RIB had a marginally higher duration of hospital stay, which approached statistical significance (mean difference: 3.71 days [\u22120.18, 7.59]; I2 = 0%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both RIB and SCI of hypertonic saline were safe and effective for managing severe symptomatic hyponatremia. The reduced duration of hospital stay with SCI of hypertonic saline may suggest this may be the optimal way of administering hypertonic saline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_249_24","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:00:20Z","timestamp":1741352420000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Rapid Intermittent Bolus versus Slow Continuous Infusion of Hypertonic Saline for Managing Symptomatic Severe Hyponatremia: A Systematic Review and Meta-analysis"],"prefix":"10.4103","volume":"24","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism Superspeciality Healthcare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Maharishi Markandeshwar Institute of Medical Sciences, Ambala, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bhaktivedanta Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Endocrinology, Diabetes, Arthritis and Rheumatism Superspeciality Healthcare, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/clinem\/dgac685","article-title":"Association of preoperative hyponatremia with surgical outcomes: A systematic review and meta-analysis of 32 observational studies","volume":"108","author":"Teo","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1574887118666221208161259","article-title":"Hyponatremia related to neurocritical care: Focus on diagnosis and therapy: A systematic review","volume":"18","author":"Mezzini","year":"2023","journal-title":"Rev Recent Clin Trials"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.02.021","article-title":"Association of hyponatremia and risk of short- and long-term mortality in patients with stroke: A systematic review and meta-analysis","volume":"28","author":"Chen","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ejendo\/lvad028","article-title":"Overcorrection and undercorrection with fixed dosing of bolus hypertonic saline for symptomatic hyponatremia","volume":"188","author":"Pelouto","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"R6-20260423","first-page":"47","article-title":"Osmotic demyelination as a complication of hyponatremia correction: A systematic review","volume":"46","author":"Bastos","year":"2024","journal-title":"J Bras Nefrol"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"504","DOI":"10.23876\/j.krcp.20.226","article-title":"Optimal treatment with hypertonic saline in patients with symptomatic hyponatremia: A perspective from a randomized clinical trial (SALSA trial)","volume":"39","author":"Baek","year":"2020","journal-title":"Kidney Res Clin Pract"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamainternmed.2020.5519","article-title":"Risk of overcorrection in rapid intermittent bolus versus slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia: The SALSA randomized clinical trial","volume":"181","author":"Baek","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1210\/jc.2019-00044","article-title":"Continuous versus bolus infusion of hypertonic saline in the treatment of symptomatic hyponatremia caused by SIAD","volume":"104","author":"Garrahy","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EJE-20-1207","article-title":"Treatment of symptomatic hyponatremia with hypertonic saline: A real-life observational study","volume":"184","author":"Chifu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: A meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/2279-042X.132710","article-title":"A prospective study to compare the clinical efficacy of tolvaptan with 3% hypertonic saline solution in hospitalized patients having hyponatremia","volume":"3","author":"Vilapurathu","year":"2014","journal-title":"J Res Pharm Pract"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4103\/0972-5229.195708","article-title":"Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary intensive care unit","volume":"20","author":"Reddy","year":"2016","journal-title":"Indian J Crit Care Med"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14797\/mdcj-9-1-49","article-title":"Efficacy of 3% saline versus conivaptan in achieving hyponatremia treatment goals","volume":"9","author":"Dominguez","year":"2013","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"5483.","DOI":"10.3390\/jcm12175483","article-title":"Safety and efficacy of vaptans in the treatment of hyponatremia from syndrome of inappropriate antidiuretic hormone secretion (SIADH): A systematic review and meta-analysis","volume":"12","author":"Krisanapan","year":"2023","journal-title":"J Clin Med"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"e13939.","DOI":"10.1111\/ijcp.13939","article-title":"Risks of vaptans in hypernatremia and serum sodium overcorrection: A systematic review and meta-analysis of randomised controlled trials","volume":"75","author":"Zhou","year":"2021","journal-title":"Int J Clin Pract"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJM200507283530424","article-title":"Hyponatremia in marathon runners","volume":"353","author":"Ayus","year":"2005","journal-title":"N Engl J Med"},{"key":"R23-20260423","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/bjsports-2015-095004","article-title":"Statement of the 3rd international exercise-associated hyponatremia consensus development conference, Carlsbad, California, 2015","volume":"49","author":"Hew-Butler","year":"2015","journal-title":"Br J Sports Med"},{"key":"R24-20260423","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1681\/ASN.2016101139","article-title":"Diagnosis and treatment of hyponatremia: Compilation of the guidelines","volume":"28","author":"Hoorn","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R25-20260423","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.beem.2015.12.001","article-title":"Diagnosis and treatment of hyponatraemia","volume":"30","author":"Ball","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_249_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:01Z","timestamp":1786647661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_249_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_249_24","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}